Strategic Partnerships Prellis Biologics has a history of high-profile collaborations with major pharma players, including Bristol Myers Squibb and Sanofi, and a current collaboration with Lilly. These established relationships indicate a market receptiveness to external collaboration and potential for cross-selling or expanding into joint development programs with similar large-cap biopharma or vaccine companies.

Immunology Focus The company is actively expanding its EXIS platform for externalized immune system applications such as antibody discovery, immunogenicity, and vaccine screening. This signals ongoing demand in antibody therapeutics and vaccine development spaces, offering sales opportunities to CROs, biotech startups, and pharma companies seeking turnkey immune-system–centric discovery platforms.

Funding Momentum With a Series C funding of $35M in 2022 and total funding of $79M, plus revenue in the mid-range, Prellis demonstrates financial backing and growth trajectory. This financial stability can support joint ventures, co-development deals, or technology licensing arrangements with risk-tolerant partners looking for innovation in bioprinting and tissue engineering.

High-Value Tech Stack The utilization of advanced technologies like RT-qPCR, PyTorch, GraphQL, AWS Glue, and bioprinting capabilities suggests readiness to integrate with partners’ data platforms and analytical pipelines. This opens opportunities for technology licensing, integration partnerships, or purpose-built assay collaborations with teams prioritizing scalable data workflows and AI-driven discovery.

Growth and Talent An ongoing hiring focus on immunologists and expansion of externalized immune system capabilities implies scalability and readiness to support expanded programs. This presents a sales opportunity to provide support services, reagent supply, contract research, or training services aligned with scaling discovery and screening efforts for potential customers pursuing rapid antibody and vaccine projects.